SOURCE: Sunshine Biopharma Inc.

Sunshine Biopharma Inc.

January 20, 2016 09:30 ET

Sunshine Biopharma Is Moving Forward With Its Development Plans for Adva-27a Anticancer Compound

MONTREAL, QC--(Marketwired - Jan 20, 2016) -  Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, announced today that it is moving forward with its plans for the development of Adva-27a and to this end it has recently acquired all of the rights, title and interest in and to all worldwide patents for the Adva-27a anticancer compound. In addition, the Company is currently in discussions with several investment groups for the purposes of securing funding for Adva-27a development through Phase I clinical trials. Adva-27a has proven to be effective at killing Multidrug Resistant Cancer cells including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells and Uterine Sarcoma cells (Results published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). The Company is planning Phase I clinical trials of Adva-27a on Pancreatic Cancer and, in parallel, Multidrug Resistant Breast Cancer patient volunteers to be conducted at McGill University's Jewish General Hospital in Montreal (Canada).

About Adva-27a

Adva-27a is Sunshine Biopharma's lead anticancer compound, a Topoisomerase II inhibitor, small molecule that has recently been shown to be effective at killing Multidrug Resistant Breast Cancer cells, Pancreatic Cancer cells, Small-Cell Lung Cancer cells and Uterine Sarcoma cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Sunshine Biopharma is direct owner of all issued and pending worldwide patents pertaining to Adva-27a including U.S. Patent Number 8,236,935. Adva-27a is currently in the IND-Enabling stage of development. The Company is planning Phase I clinical trials of Adva-27a for Pancreatic Cancer and in parallel Multidrug Resistant Breast Cancer to be conducted at McGill University's Jewish General Hospital in Montreal (Canada).

Safe Harbor Forward-Looking Statements

To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

Contact Information